Athlome Project Consortium, and Erskine, RM Athlome Project Consortium: a concerted effort to discover genomic and other "omic" markers of athletic performance.
49
Despite numerous attempts to discover genetic variants associated with elite athletic 50 performance, injury predisposition and elite/world-class athletic status, there has been limited 51 progress to date. Past reliance on candidate gene studies predominantly focusing on genotyping a 52 limited number of single nucleotide polymorphisms (SNPs) or the insertion/deletion variants in 53 small, often heterogeneous cohorts (i.e., made up of athletes of quite different sport specialties) 54 have not generated the kind of results that could offer solid opportunities to bridge the gap 55 between basic research in exercise sciences and deliverables in biomedicine. A retrospective 56 view of genetic association studies with complex disease traits indicates that transition to 57 hypothesis-free genome-wide approaches will be more fruitful. In studies of complex disease, it 58 is well recognized that the magnitude of genetic association is often smaller than initially 59 anticipated and, as such, large sample sizes are required to identify the gene effects robustly.
60
Thus, alternative large-scale, collaborative efforts involving well-phenotyped male and female 61 cohorts from which high-resolution genome-wide data is generated and interrogated using 62 advanced bioinformatics approaches are necessary for meaningful progress to be made.
63
Accordingly, a symposium was held in Athens and on the Greek island of Santorini from 14-17th
64
May 2015 (http://celebratorysymposium.net) to review the main findings in exercise genetics and 65 genomics and to explore promising trends and possibilities. The symposium also offered a forum 66 for the development of a position stand (the Santorini Declaration). Among the participants, 67 many were involved in ongoing collaborative studies (e.g., GAMES, Gene SMART, GENESIS 68 and POWERGENE). A consensus emerged among participants that it would be advantageous to 69 bring together all current studies and those recently launched into one new large collaborative 70 initiative, which was subsequently named the Athlome Project Consortium.
72
At the outset, the Athlome Project aims to collectively study the genotype and phenotype data 73 currently available on elite athletes, in adaptation to exercise training (in both human and animal 74 models) and on exercise-related musculoskeletal injuries from individual studies and from 75 consortia worldwide. To achieve this, several steps are set out: 
GENESIS

185
The GENetics of Elite Status In Sport (GENESIS) consortium aims to identify molecular genetic significance of the identified variants will also be investigated. This initial phase will be 229 followed by sequencing and the research objectives will be eventually expanded to include other "omics". Thus far, ACL rupture consortium has collected DNA samples and clinical, as well as 231 physical and occupational activity information from subjects from South Africa, Poland, 
J-HAP
239
The Japanese Human Athlome Project (J-HAP) focuses on the study of genes associated with 240 physical performance and its related phenotypes (e.g., muscle mass, muscle fiber type, V O 2 max).
241
The cohort is comprised of Japanese athletes (currently > 2,400, mainly international and 242 national levels) and healthy Japanese controls (currently > 1,000). These athletes are mainly 243 track-and-field athletes and swimmers competing in endurance-and sprint/power-oriented events.
244
Multiple "omics" approaches will be used to determine genes in talent identification in the 
Super-athletes: Genes and Sweat
290
The study aims to (i) identify genetic variants associated with elite athletic performance, (ii) 291 study potential ethnic differences, and (iii) study the functional significance of the identified variants. A GWAS will be carried out in 3,000 consented elite athletes, tested negative for 293 doping substances at the Anti-Doping Laboratories, Federazione Medico Sportiva Italiana
294
(FMSI) and Anti-Doping Lab Qatar (ADLQ), using Illumina genotyping technologies.
295
Examining genotype frequency distribution of elite athletes from European countries (where 296 most of FMSI samples will be obtained) against those from South Asian and African countries 297 (where most of ADLQ samples are expected to be obtained) would help to identify potential 298 ethnic differences in the genetic predisposition to athletic performance. Subsequently, urine 299 metabolome in a subset of these athletes (1,000 subjects) will be performed, and will be related 300 to the athlete's sporting discipline. 
Rat models of exercise and health (LCR-HCR rat model)
322
The purpose of the Low Capacity Rats-High Capacity Rats (LCR-HCR) model is to serve as a 323 resource for the in-depth study of rat models to resolve the extremes of exercise and health. By 324 connecting clinical observation with a theoretical base, the working hypothesis is that: variation 325 in capacity for energy transfer is the central mechanistic determinant between disease and 326 health (energy transfer hypothesis). As an unbiased test of this hypothesis, this study showed that 327 two-way artificial selective breeding of rats for low and high intrinsic endurance exercise 328 capacity also produced rats that differed for numerous disease risks, including the metabolic 329 syndrome, premature aging, fatty liver disease, obesity, and Alzheimer's disease. Exercise 330 capacity is a result of intrinsic capacity plus adaptation to all aspects of physical activity. To 331 capture this biology, rats for low and high response to 8 weeks of treadmill running exercise 332 were selectively bred. Thus, the study has models that represent the 4 "corners" of exercise 333 capacity. These contrasting animal model systems may prove to be translationally superior 334 relative to more widely used simplistic models for understanding disease conditions. The rat 335 models may be deeply explored to discover causal mechanisms and develop effective 336 therapeutics. These rats are being studied at over 50 institutions in 11 countries. to be generated from the 1000 Athlome project will serve 1) as a reference panel for future 349 performance studies, and 2) to guide other extreme phenotype studies in medical science.
Ethical Principles for Athlome biobanking
355
The rise of biobanking has brought about a whole range of issues that are not all wholly relevant 356 to the Athlome project. Nevertheless, certain key principles must be noted here that will inform 357 the governance framework for Athlome: (i) the consortia are global in reach but there is no 358 universal agreement on the precise nature of ethically justifiable governance for biobanking; (ii)
359
given the globality of the consortia, no single regional (e.g., European, American) framework 360 ought to be adopted; (iii) a general framework drawing on widely shared principles should be 361 discussed and adopted. Chief among the concerns, but only one among several, is the problem of 362 consent.
364
Each of the projects that comprise Athlome are existing bio-guardians with a duty to protect the 365 rights of participants who have contributed their samples to the individual projects noted above.
366
The collection, storage, access to and use by researchers of those samples has been approved by consider the use of a technique such as "broad consent". The nomenclature here is important 380 since this notion is variously described as "broad consent", "blanket consent", "future consent", 381 "hypothetical consent", "passive/tacit/silent consent", or "waived consent" (4,5). This would 382 entail asking participants to agree to future unspecified uses o f t h e i r d a t a t h a t a r e 383 und(er)determined in the consent process and relevant forms (6). Without sufficient grasp of the In conclusion, by presenting the main study cohorts and projects that are currently included in 405 the Athlome consortium it is our intention to show a global view not only of the main studies and 406 initiatives that will be performed in the foreseeable future in the field of sports genomics (and 407 that are likely to provide new exciting findings); we also wish to motivate potential collaboration 408 initiatives with other research groups worldwide. International collaborations are likely to go 409 well beyond the study of sports performance per se. Indeed, the Athlome consortium presents a 410 unique chance to study the biology of the best elite athletes across most ethnicities, which is 411 profoundly interesting from a medical point of view. World-class athletes represent the actual 412 end-point of the human continuum of fitness-related phenotypes. In this regard, there is growing 413 evidence (coming from both human and rodent study approaches -such as those included in the 414 consortium) that not only physical activity levels but also individual fitness levels (a trait which has a strong genetic component independent of activity levels) are inversely associated with the 416 risk of major cardiometabolic diseases of western civilization, several cancer types and 417 Alzheimer's disease. Thus, studying the genes of elite athletes offers a unique chance to gain 418 insight into important medical, including genetic predisposition (or resilience) to chronic disease. 
